PRIVI SPECIALITY CHEM Q3FY24 CONS
NET PROFIT 29 CR VS 6 CR (YOY) , Q2 30 CR
REVENUE 404 CR VS 420 CR (YOY), Q2 455 CR
EBITDA 90 CR VS 47 CR (YOY) , Q2 86 CR
EBITDA MARGIN 22% VS 12% (YOY) , Q2 20%
Margin Expansion
Concall Results https://www.privi.com/Downloads/Notices/2023-2024/outcome/Privi-Speciality-Chemicals-3QFY24-Concall-Audio.mp3
CST As of Dec 2023